Send to

Choose Destination
Ann Transl Med. 2018 Feb;6(3):57. doi: 10.21037/atm.2017.12.13.

Osimertinib in first-line treatment-is a comparison not proof?

Author information

Chest Department and Expert Center in Thoracic Oncology, Hôpital Tenon/AP-HP and Pierre & Marie Curie University Paris 6, Paris, France.

Conflict of interest statement

Conflicts of Interest: The author declares conflicts of interest with Astra-Zeneca, Roche, Bohringer Ingelheim receiving personal fees for participating to expert board or being an investigator of several trials.

Supplemental Content

Full text links

Icon for AME Publishing Company Icon for PubMed Central
Loading ...
Support Center